Mark Yarchoan, MDAssociate Professor of OncologyJohns Hopkins Kimmel Cancer CenterDr. Mark Yarchoan is pioneering physician-scientist who is focused on changing the trajectory of gastrointestinal cancers by conducting groundbreaking research and teaching future generations of oncologists. In his role, Dr. Yarchoan has honed in on optimizing the use of immunotherapy with cancer-specific vaccines.He currently leads several clinical trials targeting bile duct and liver cancers. His research has shown that, in many cases these vaccines enhance immunotherapeutic responses, helping to halt the growth of these difficult-to-treat cancers. In a recent landmark liver cancer trial, Dr. Yarchoan and his team demonstrated for the first time that a personalized vaccine could generate strong immune responses in most patients, with about one-third experiencing significant tumor shrinkage. He is also developing a cancer vaccine for fibrolamellar Hepatocellular Carcinoma (FLC), a rare and aggressive liver cancer affecting children and young adults. These studies aim to getter understand outcomes and identify new strategies to "reboot" the immune system against cancer. While the progress to date is encouraging and the future holds great promise, significant challenges remain. A June 29 segment of CBS Sunday Morning by veteran journalist Ted Koppel,, titled "Saving Money vs. Saving Lives," highlighted the state of cancer research and the potential implications for patients and researchers like Dr. Yarchoan.
Thank you for your support, should you have questions please contact Anne Kennan at akennan1@jhmi.edu
Signing in with your Johns Hopkins account will automatically fill in your name and address information in the next step of making your submission. Selecting Continue as Guest will allow you to submit without signing in to an existing Johns Hopkins account.
